HUE066864T2 - Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében - Google Patents

Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében

Info

Publication number
HUE066864T2
HUE066864T2 HUE15857508A HUE15857508A HUE066864T2 HU E066864 T2 HUE066864 T2 HU E066864T2 HU E15857508 A HUE15857508 A HU E15857508A HU E15857508 A HUE15857508 A HU E15857508A HU E066864 T2 HUE066864 T2 HU E066864T2
Authority
HU
Hungary
Prior art keywords
pyrimidines
treatment
medical disorders
substituted pyrazolo
pyrazolo
Prior art date
Application number
HUE15857508A
Other languages
English (en)
Hungarian (hu)
Inventor
Renato Skerlj
Peter Lansbury
Andrew Good
Elyse Bourque
Original Assignee
Bial R&D Invest S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial R&D Invest S A filed Critical Bial R&D Invest S A
Publication of HUE066864T2 publication Critical patent/HUE066864T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE15857508A 2014-11-06 2015-11-06 Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében HUE066864T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462076062P 2014-11-06 2014-11-06

Publications (1)

Publication Number Publication Date
HUE066864T2 true HUE066864T2 (hu) 2024-09-28

Family

ID=55909884

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE15857508A HUE066864T2 (hu) 2014-11-06 2015-11-06 Helyettesített pirazolo(1,5-a)pirimidinek és alkalmazásuk orvosi rendellenességek kezelésében

Country Status (21)

Country Link
US (5) US10570135B2 (https=)
EP (2) EP4406616A3 (https=)
JP (2) JP6734860B2 (https=)
KR (1) KR102662215B1 (https=)
CN (2) CN115925711A (https=)
AU (1) AU2015342887B2 (https=)
DK (1) DK3215511T3 (https=)
EA (1) EA201790995A1 (https=)
ES (1) ES2984482T3 (https=)
FI (1) FI3215511T3 (https=)
HR (1) HRP20240644T1 (https=)
HU (1) HUE066864T2 (https=)
IL (1) IL252053B2 (https=)
LT (1) LT3215511T (https=)
MX (1) MX394094B (https=)
PL (1) PL3215511T3 (https=)
PT (1) PT3215511T (https=)
RS (1) RS65642B1 (https=)
SI (1) SI3215511T1 (https=)
SM (1) SMT202400187T1 (https=)
WO (1) WO2016073895A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366688B1 (en) * 2010-12-08 2022-02-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
EP4406616A3 (en) * 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
CN108473498B (zh) 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
EP3429590A4 (en) * 2016-03-16 2020-02-19 Lysosomal Therapeutics Inc. METHOD AND COMPOSITIONS FOR THE TREATMENT OF A NEURODEGENERATIVE DISEASE IN A SUBJECT CARRIING THE SPHINGOLIPIDOSIS GENE
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3440081A4 (en) * 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CN109890829B (zh) 2016-11-02 2022-07-15 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
CN110325516A (zh) 2016-12-29 2019-10-11 米尼奥尔克斯治疗有限公司 杂芳基化合物和它们的用途
MX387969B (es) 2017-05-22 2025-03-19 Hoffmann La Roche Composiciones y compuestos terapéuticos, y métodos para su uso.
US12064414B2 (en) * 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
JP2021506920A (ja) * 2017-12-21 2021-02-22 リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用
WO2019151269A1 (ja) 2018-01-31 2019-08-08 武田薬品工業株式会社 複素環化合物
IT201800006067A1 (it) * 2018-06-06 2019-12-06 Nuovi inibitori della diidroortato deidrogenasi umana (hDHODH) e loro uso mirato sul differenziamento mieloide.
CN113271940A (zh) * 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
CN111217816B (zh) * 2018-11-27 2022-08-16 中国科学院上海药物研究所 一类flt3激酶抑制剂及其制备和应用
GB202211999D0 (en) * 2022-08-17 2022-09-28 Mironid Ltd Compounds and their use as PDE4 activators
WO2025198486A1 (en) 2024-03-22 2025-09-25 BIAL – R&D Investments, S.A. Process for preparing a pyrazolo[1,5-a]pyrimidinyl carboxamide compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838925A (en) 1986-04-25 1989-06-13 E. I. Du Pont De Nemours And Company Heterocyclic acyl sulfonamides
JP3763997B2 (ja) 1999-05-13 2006-04-05 富士写真フイルム株式会社 感熱記録材料
JP4331823B2 (ja) 1999-05-21 2009-09-16 富士フイルム株式会社 ピロロ［１，２−ａ］−１，３，５−トリアジン−４−オン系化合物
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
JP4070966B2 (ja) 2001-06-28 2008-04-02 株式会社カネボウ化粧品 新規ガラクトシルセラミド類縁体及び用途
WO2003035649A1 (en) 2001-10-22 2003-05-01 Pfizer Japan Inc. Imidazopyridine compounds as 5-ht4 receptor modulators
CN1281606C (zh) 2002-03-01 2006-10-25 安斯泰来制药有限公司 含氮杂环化合物
DOP2003000703A (es) 2002-09-20 2004-03-31 Pfizer Compuestos de imidazopiradina como agonistas del receptor 5-ht4
JP2006502180A (ja) 2002-09-20 2006-01-19 ファイザー株式会社 ５−ｈｔ４レセプターモジュレーターとしてのｎ−置換されたピペリジニル−イミダゾピリジン化合物
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
BRPI0409592A (pt) 2003-04-21 2006-05-02 Pfizer compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
CA2545433A1 (en) 2003-11-12 2005-05-26 Amicus Therapeutics Inc. Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AU2005212096B2 (en) 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
US8318724B2 (en) 2004-05-14 2012-11-27 The Cleveland Clinic Foundation Small molecule inhibitors of MRP1 and other multidrug transporters
BRPI0512330A (pt) 2004-06-21 2008-02-26 Hoffmann La Roche derivados de pirazol-pirimidina
EP1778685B1 (de) 2004-08-02 2008-03-26 Schwarz Pharma Ag Carboxamide des indolizins und seiner aza- und diazaderivate
DE102004049363A1 (de) 2004-10-08 2006-04-13 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
CN101107251A (zh) 2005-01-19 2008-01-16 默克公司 用于治疗或预防糖尿病的作为二肽基肽酶-ⅳ抑制剂的双环嘧啶类
BRPI0607927A2 (pt) 2005-02-11 2009-10-20 Hoffmann La Roche derivados de pirazol-pirimidina
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
JPWO2006115168A1 (ja) 2005-04-21 2008-12-18 大日本住友製薬株式会社 Ｎ−置換フェニルアセトアミド誘導体およびそれを含有する医薬組成物
US7906522B2 (en) 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
AR057979A1 (es) 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
US8372851B2 (en) 2005-10-21 2013-02-12 Exelixis, Inc. Pyrazolo pyrimidines as casein kinase II (CK2) modulators
CA2629743A1 (en) 2005-12-08 2007-06-14 Novartis Ag Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2007150064A2 (en) 2006-06-23 2007-12-27 Amicus Therapeutics, Inc. METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
WO2008019363A2 (en) 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-alkylbenzoxazole carboxamides as 5ht3 modulators
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
CA2670044A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
CA2682016A1 (en) 2007-03-28 2008-10-02 Inovacia Ab Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
WO2008157575A1 (en) 2007-06-21 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
CN101970440A (zh) 2007-11-28 2011-02-09 先灵公司 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
WO2009119088A1 (ja) 2008-03-25 2009-10-01 武田薬品工業株式会社 複素環化合物
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
UY32174A (es) 2008-10-14 2010-05-31 Astrazeneca Ab Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EP2348860B1 (en) * 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CN110003219A (zh) * 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP3366688B1 (en) * 2010-12-08 2022-02-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
US9169260B2 (en) * 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
CA2840224C (en) 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
PH12014500326B1 (en) 2011-08-18 2018-01-10 Nippon Shinyaku Co Ltd Heterocyclic derivative and pharmaceutical drug
CN104039784B (zh) 2011-09-02 2017-08-22 拜耳知识产权有限责任公司 取代的增环嘧啶及其用途
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
JP6073343B2 (ja) 2011-10-20 2017-02-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
EP2794592A1 (en) 2011-12-23 2014-10-29 Novartis AG Compounds for inhibiting the interaction of bcl2 with binding partners
US9340549B2 (en) * 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
WO2013134219A1 (en) 2012-03-09 2013-09-12 Lexicon Pharmaceuticals, Inc. Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
DK2822555T3 (en) 2012-03-09 2018-02-05 Lexicon Pharmaceuticals Inc Inhibition of adapter-associated kinase 1 for the treatment of pain
JP2015512913A (ja) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ グルコセレブロシダーゼ活性剤として有用なサリチル酸誘導体
JP6231085B2 (ja) 2012-05-31 2017-11-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト アミノキナゾリン誘導体及びピリドピリミジン誘導体
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
WO2014025651A1 (en) * 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
US20150216168A1 (en) 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
CA2889919C (en) 2012-11-16 2021-08-17 University Health Network Pyrazolopyrimidine compounds
HK1215579A1 (zh) 2012-11-29 2016-09-02 Karyopharm Therapeutics, Inc. 被取代的2，3-二氫苯並呋喃基化合物和其用途
SI2941432T1 (en) * 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
KR20140086002A (ko) 2012-12-28 2014-07-08 한미약품 주식회사 Fms 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체
US9963452B2 (en) 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
US20160199372A1 (en) 2013-08-20 2016-07-14 Bristol-Myers Squibb Company Imidazopyridazine kinase inhibitors useful to treating a disease or disorder mediated by aak1, such as alzheimer's disease, bipolar disorder, pain, schizophrenia
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
AR097543A1 (es) 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
EP3461812B1 (en) 2014-03-27 2021-10-13 Academisch Medisch Centrum N-(5-(biphen-4-ylmethyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US9802942B2 (en) 2015-07-01 2017-10-31 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
CN108290855A (zh) 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EP3344632A4 (en) 2015-09-04 2019-03-20 Lysosomal Therapeutics Inc. Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
PT3371190T (pt) 2015-11-06 2022-07-08 Incyte Corp Compostos heterocíclicos como inibidores de pi3k-gamma
US10479793B2 (en) 2015-11-18 2019-11-19 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
JP6936236B2 (ja) 2016-02-18 2021-09-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療化合物、組成物及びその方法の使用
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
EP3452045A1 (en) 2016-05-04 2019-03-13 Lysosomal Therapeutics Inc. Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
KR102530515B1 (ko) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. 치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
EP3452480A4 (en) 2016-05-05 2019-11-06 Lysosomal Therapeutics Inc. SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
JP2021506920A (ja) 2017-12-21 2021-02-22 リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 結晶性の置換シクロヘキシルピラゾロ［１，５−ａ］ピリミジニルカルボキサミド化合物およびその治療的使用

Also Published As

Publication number Publication date
SI3215511T1 (sl) 2024-07-31
US11932645B2 (en) 2024-03-19
IL252053B1 (en) 2023-12-01
EP3215511A1 (en) 2017-09-13
NZ731897A (en) 2023-11-24
IL252053B2 (en) 2024-04-01
JP6734860B2 (ja) 2020-08-05
FI3215511T3 (fi) 2024-05-16
JP2020183410A (ja) 2020-11-12
CN115925711A (zh) 2023-04-07
CN107001379A (zh) 2017-08-01
US11091492B2 (en) 2021-08-17
EP3215511A4 (en) 2018-02-28
US20200385390A1 (en) 2020-12-10
MX2017005940A (es) 2018-01-11
SMT202400187T1 (it) 2024-07-09
AU2015342887A1 (en) 2017-06-15
US9732089B2 (en) 2017-08-15
RS65642B1 (sr) 2024-07-31
EP4406616A2 (en) 2024-07-31
IL252053A0 (en) 2017-07-31
EP4406616A3 (en) 2024-11-06
CN107001379B (zh) 2022-11-01
ES2984482T3 (es) 2024-10-29
US20220169652A1 (en) 2022-06-02
BR112017009276A8 (pt) 2023-03-14
PL3215511T3 (pl) 2024-08-12
EA201790995A1 (ru) 2017-10-31
BR112017009276A2 (pt) 2017-12-19
US20170183354A1 (en) 2017-06-29
LT3215511T (lt) 2024-06-25
US20250066364A1 (en) 2025-02-27
JP7519221B2 (ja) 2024-07-19
KR20170082577A (ko) 2017-07-14
DK3215511T3 (da) 2024-05-13
EP3215511B1 (en) 2024-04-17
KR102662215B1 (ko) 2024-05-02
PT3215511T (pt) 2024-05-22
HRP20240644T1 (hr) 2024-08-02
JP2017533968A (ja) 2017-11-16
WO2016073895A1 (en) 2016-05-12
MX394094B (es) 2025-03-24
AU2015342887B2 (en) 2020-09-10
US20170334916A1 (en) 2017-11-23
US10570135B2 (en) 2020-02-25
CA2966583A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
PT3215511T (pt) Pirazolo(1,5-a)pirimidinas substituídas e a sua utilização no tratamento de distúrbios médicos
EP3215509A4 (en) Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
IL246564A (en) 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases
IL259751B (en) Polycyclic compounds and their use in the treatment of immune disorders
IL271117B (en) Diazabicyclic mutated imidazopyrimidines and their use in the treatment of respiratory disorders
IL262698B (en) [1,2-b]Amidazo-converted pyridazines, [1,5-b]imidazo-converted pyridazines, related compounds and their use for the treatment of medical disorders
IL262177B (en) Pyrimidinyl Carboxamide, 5-a] compounds and their use for the treatment of medical disorders
IL246579B (en) Compounds that inhibit the activity of 2lrrk and their use in the treatment of Parkinson's disease
GB2542155B (en) Use of cannabidiol in the treatment of mental disorders
EP3215510A4 (en) Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3344632A4 (en) Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
EP3452480A4 (en) SUBSTITUTED PYRROLO [1,2-] TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
IL275349A (en) Use of hM4Di in the treatment of seizure disorders
ZA201905402B (en) Compounds and their use in the treatment of schistosomiasis
ZA201701207B (en) [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
IL274838A (en) Use of MIR101 or MIR128 in the treatment of seizure disorders
EP3344625A4 (en) THIAZOLO (3,2-A) PYRIMIDINONE AND OTHER HETEROBICYCLIC COMPOUNDS OF PYRIMIDINONE FOR THERAPEUTIC USE
HK40004413A (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
HK40006031A (en) SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer
HK1248110A1 (en) Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases